OnKure Therapeutics (OKUR) Expected to Announce Earnings on Thursday

OnKure Therapeutics (NASDAQ:OKUR) is expected to be posting its results before the market opens on Thursday, November 6th. Analysts expect OnKure Therapeutics to post earnings of ($1.19) per share for the quarter.

OnKure Therapeutics (NASDAQ:OKUR) last posted its earnings results on Tuesday, August 12th. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.09. On average, analysts expect OnKure Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

OnKure Therapeutics Stock Down 5.2%

OKUR opened at $3.10 on Wednesday. The stock has a market cap of $41.94 million, a P/E ratio of -0.65 and a beta of 0.46. OnKure Therapeutics has a 12 month low of $1.70 and a 12 month high of $17.74. The company has a fifty day simple moving average of $2.82 and a 200 day simple moving average of $2.56.

Wall Street Analysts Forecast Growth

Several analysts have commented on OKUR shares. HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of OnKure Therapeutics in a report on Tuesday, August 26th. Wall Street Zen upgraded shares of OnKure Therapeutics to a “sell” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OnKure Therapeutics in a research note on Wednesday, October 8th. Finally, Zacks Research downgraded OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.33.

Hedge Funds Weigh In On OnKure Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new stake in OnKure Therapeutics in the second quarter valued at $25,000. Rangeley Capital LLC acquired a new stake in OnKure Therapeutics in the 2nd quarter valued at about $71,000. Finally, Shay Capital LLC grew its holdings in OnKure Therapeutics by 417.8% during the second quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock worth $1,869,000 after purchasing an additional 631,008 shares during the period. 90.98% of the stock is owned by institutional investors.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.